Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (53 quarters reported)
$130M in Q2 2013 → $254M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Bioventus Inc | 48.3% | Unchanged | 13,021,324 | $123M |
| Mimedx Group Inc | 42.7% | Unchanged | 28,195,249 | $109M |
| EP Eyepoint Pharmaceuticals Inc | 6.1% | Unchanged | 1,084,857 | $15.5M |
| Tela Bio Inc | 2.3% | Unchanged | 7,714,709 | $5.79M |
| Medicinova Inc | 0.6% | Unchanged | 1,105,941 | $1.46M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 04, 2026
No position changes this quarter.
quarter ended March 31, 2026 · filed May 04, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Venus Concept Inc | Exited | −99,021 | −$147K | — |
quarter ended December 31, 2025 · filed February 04, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Tela Bio Inc | Added | +3,604,000 | +$4.25M | 2.9% |
quarter ended September 30, 2025 · filed November 12, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| EP Eyepoint Pharmaceuticals Inc | Trimmed | −85,000 | −$1.21M | 5.0% |
quarter ended June 30, 2025 · filed August 07, 2025
No position changes this quarter.
quarter ended March 31, 2025 · filed May 13, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| RT Revance Therapeutics Inc | Exited | −457,085 | −$1.39M | — |
| Venus Concept, Inc. | Exited | −1,089,190 | −$414K | — |
| Venus Concept Inc | New | +99,021 | +$276K | 0.1% |
quarter ended December 31, 2024 · filed February 13, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| EP Eyepoint Pharmaceuticals Inc | Trimmed | −381,664 | −$2.84M | 2.0% |
quarter ended September 30, 2024 · filed November 14, 2024
No position changes this quarter.
Loading...
